A few notes / highlights:
*had mid cycle review with the FDA regarding Otrexup and are confident of its success in achieving the advertised PDUFA date in October.
*exhibiting "highly controlled spending" as they ramp up for Otrexup launch
*First user study has been completed for QS T - similar path as Otrexup.
*in position to "DOMINATE the subcutaneous space" with the Vibex technology combination products platform. I really liked this statement!
*QS M (Neurologic) - intellectual property is being worked on and once all this is in place, the drug will be announced.
Otherwise, the main focus was on their injector platform, everything else is ancillary and not surprising, at least to me, as they have been clearly broadcasting this directive for some time now.
News 
Market Data 
Discover 
AI
